Barclays
EDIT icon

Barclays’s Editas Medicine EDIT Stock Holding History

Barclays’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,900
Closed -$68K – 7183
2018
Q2 		$68K Buy
+1,900
New +$67.3K ﹤0.01% 5471

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
Kennedy Capital Management
Kennedy Capital Management St Louis, Missouri $5.31B AUM 40.5% 1-Year Est. Return

Barclays's EDIT Position: Q3 2026 in Review

Barclays increased its Editas Medicine (EDIT) stake by 242% in Q3 2026, buying an estimated $1.06M and bringing the position to 510,903 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2863.

Barclays first reported a position in EDIT in Q1 2016 and has held it in 42 quarters since. The position peaked at $4.39M in Q1 2021. 151 funds tracked by Wall St. Rank hold EDIT as of Q3 2026.

  • Barclays held 510,903 shares of Editas Medicine worth $1.31M as of Q3 2026.
  • Barclays bought 361,639 Editas Medicine shares in Q3 2026, an estimated $1.06M.
  • Editas Medicine made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2863 holding.
  • Barclays first reported a position in Editas Medicine in Q1 2016 and has held it in 42 quarters since.
  • Barclays's Editas Medicine position peaked at $4.39M in Q1 2021.
  • 151 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.